Co-Diagnostics, Inc.

CODX Details

Co-Diagnostics, Inc. (NASDAQ: CODX) specializes in molecular diagnostics. It creates, licenses, and sells molecular technologies such as lab systems (MDx devices) and manufactures and sells reagents for tests that rely on nucleic acid molecule detection and analysis.

Why should Investors exit?

• Customer Concentration Risk: In the third quarter ended September 30, 2021, company’s two clients contributed roughly 55% in the total income, implies a significant customer concentration risk.
• Rising Uncertainties: The Russia-Ukraine stand-off can continue to weigh on the equity market, as it has severely impacted commodities prices in the international markets which can have an elongated impact on the overall stock market performance. Therefore, small-caps and penny-caps could be higher volatile compared to their large-cap counterparts.
• Technical Weakness:  The broader trend in the stock is quite bearish, with stock hovering below its crucial long-term as well as short-term support levels of 200-day and 50-day SMAs. Moreover, the moving averages are coming down another bearish trend.    
• Bearish Candle Sticks Pattern on Weekly Price Chart: On weekly price chart, the stock is forming a lower top and lower bottom kind of pattern and falling consistently since February 2021, except couple of fake spikes. Also, the leading momentum indicator 14-Period RSI is hovering in a neutral zone, with bearish bias at 41.
• Decrease in Bottom Line: In Q3 FY21, the net income of the company has come down to USD 11.47 million from USD 15.73 million in Q3 FY20.

Valuation Methodology: EV/Sales Multiple Based Relative Valuation

Source: Analysis by Kalkine Group

Stock Recommendation:

CODX shares are hovering in a long-term bearish zone and forming a lower top and lower bottom kind of price patten on the daily price chart, a bearish indicator. Moreover, 14-period Relative Strength Index (RSI) is hovering in a neutral zone, with bearish bias.

Further, despite decent topline and gross profit numbers reported by the company in the quarter just gone by, company has failed to pass the same in the bottom-line performance and Basic EPS has decline from USD 0.56 in Q3FY20 to USD 0.40 in Q3FY21.

Given the penny-cap market categorization of the stock and rising volatility in the global equity market in the wake of Russia-Ukraine standoff, we believe CODX shares could be highly volatile in near-term.  CODX’s share price made a 52-week high and low of USD 14.97 and USD 5.00 and currently tilted towards the 52w low, another bearish indicator. Hence, we recommend a “SELL" rating on the stock at the closing price of USD 6.55, down by 0.15%, as of March 18, 2022.

1-year Technical Price Chart (as of March 18, 2022). Source: REFINITIV, Analysis by Kalkine Group

*The reference data in this report has been partly sourced from REFINITIV.

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website unless those persons comply with certain safeguards, procedures, and disclosures.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.